Spruce Biosciences
SPRB
45 hedge funds and large institutions have $459M invested in Spruce Biosciences in 2020 Q4 according to their latest regulatory filings, with 45 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$110M |
| 2 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
+$47.8M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$37.6M |
| 4 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$36M |
| 5 |
ACM
Aisling Capital Management
New York
|
+$26.6M |
Top Sellers
SPRB Hedge Fund Activity: Q4 2020 in Review
45 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Spruce Biosciences (SPRB) for Q4 2020, worth a combined $459M.
Buyers outnumbered sellers: 45 funds opened new SPRB positions and 0 closed out — a net gain of 45 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Novo Holdings A/S, opening a new position worth an estimated $110M.
- 45 institutional investors held Spruce Biosciences (SPRB) as of Q4 2020, up from 0 in Q3 2020.
- Funds reported $459M of Spruce Biosciences stock for Q4 2020.
- 45 funds opened new Spruce Biosciences positions in Q4 2020 and 0 closed out, a net change of +45 holders.
- The largest Spruce Biosciences buyer in Q4 2020 was Novo Holdings A/S, an estimated $110M added.
Based on aggregated 13F filings for Q4 2020.